IL6 and metabolic dysfunction-associated steatotic liver disease: Another previous study found that 7.1% weight loss, 22.3% visceral adiposity reduction, 15.5% improvement in HOMA-IR and lipid profiles, and inflammatory biomarkers (hs-CRP, −29.5%; IL-6, −18.2%; TNF-α, −34.2%) following energy-restricted anti-inflammatory diet therapy for patients with nonalcoholic fatty liver disease [49].